8-K: Wave Life Sciences Reports Q1 2024 Results, Advances RNA Medicine Pipeline

Wave Life Sciences announced its first quarter 2024 financial results and provided updates on its RNA medicine programs, including progress in clinical trials and collaborations.

Summary

• Wave Life Sciences reported a net loss of $31.6 million for the first quarter of 2024, compared to a net loss of $27.4 million in the same period of 2023.
• The company's revenue was $12.5 million for the first quarter of 2024, slightly down from $12.9 million in the first quarter of 2023 due to decreased revenue from the Takeda collaboration.
• Research and development expenses increased to $33.4 million in Q1 2024 from $31.0 million in Q1 2023.
• General and administrative expenses also rose to $13.5 million in Q1 2024 from $12.2 million in Q1 2023.
• As of March 31, 2024, Wave had $181 million in cash and cash equivalents, with an additional $12 million received from GSK after the quarter ended.
• The company expects its current cash to fund operations into the fourth quarter of 2025.
• Wave is advancing its RestorAATion-2 clinical trial for WVE-006 in AATD patients, with proof-of-mechanism data expected in 2024.
• A clinical trial for the INHBE program for obesity is expected to begin in the first quarter of 2025.
• The company is also progressing its FORWARD-53 trial in DMD, with potentially registrational data expected in the third quarter of 2024.
• Multi-dose data for the allele-selective HD program is expected in the second quarter of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and collaborations, the increased net loss and slight revenue decrease temper the overall sentiment. The company's strong cash position and pipeline advancements are encouraging, but the financial results are a concern.

Positives

• The RestorAATion-2 clinical trial for WVE-006 in AATD is underway and on track to deliver proof-of-mechanism data in 2024.
• Preclinical data for the INHBE program in obesity showed promising results, including weight loss similar to semaglutide and no loss of muscle mass.
• The company's collaboration with GSK is progressing well, with two programs selected for development and a $12 million initiation payment received.
• The FORWARD-53 trial in DMD is advancing towards potentially registrational data in the third quarter of 2024.
• Wave has a strong cash position of $181 million, with an additional $12 million received from GSK, providing a cash runway into the fourth quarter of 2025.
• The company is advancing a diverse pipeline of RNA medicines, including RNA editing, siRNA, splicing, and antisense technologies.
• Wave has appointed Dr. Erik Ingelsson as Chief Scientific Officer, bringing expertise in genetics and drug discovery.

Negatives

• Wave Life Sciences reported a net loss of $31.6 million for the first quarter of 2024, which is an increase from the $27.4 million loss in the same period of 2023.
• Revenue decreased slightly to $12.5 million in Q1 2024 from $12.9 million in Q1 2023 due to decreased revenue from the Takeda collaboration.
• Research and development expenses increased to $33.4 million in Q1 2024 from $31.0 million in Q1 2023.
• General and administrative expenses also increased to $13.5 million in Q1 2024 from $12.2 million in Q1 2023.

Risks

• The company's ability to finance its drug discovery and development efforts and to raise additional capital when needed is a risk.
• Clinical trial results may not support further development of product candidates.
• Actions of regulatory authorities may affect the initiation, timing, and progress of clinical trials.
• The company is dependent on third parties, including contract research organizations and contract manufacturing organizations.
• Competition from others developing therapies for the same indications is a risk.
• The company's ability to maintain the infrastructure and personnel needed to achieve its goals is a risk.

Future Outlook

Wave Life Sciences expects to deliver key data sets in 2024, including proof-of-mechanism data for WVE-006 in AATD, multi-dose data for the allele-selective HD program, and potentially registrational data from the FORWARD-53 trial in DMD. The company also anticipates initiating a clinical trial for its INHBE program in obesity in the first quarter of 2025. The company expects its current cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2025.

Management Comments

• Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences, stated that the company has made excellent progress across its multimodal pipeline of novel RNA medicines and continued to advance its collaboration with GSK.
• Dr. Bolno also mentioned that the company is on-track to deliver key data sets this year, which enable opportunities to unlock the broad potential of its RNA editing, silencing and splicing capabilities.
• Dr. Bolno noted that the company is working expeditiously to advance its GalNAc-siRNA INHBE program in obesity and expects to initiate a clinical trial in the first quarter of next year.

Industry Context

This announcement highlights Wave Life Sciences' progress in the competitive RNA therapeutics space. The company's focus on multiple modalities, including RNA editing, siRNA, and antisense, positions it to address a wide range of diseases. The collaboration with GSK and the advancement of clinical programs in AATD, DMD, and HD demonstrate the company's commitment to developing innovative treatments. The obesity program also places them in a high growth area of the market.

Comparison to Industry Standards

• Wave's WVE-N531 program for DMD demonstrated industry-leading exon skipping levels of 53%, which is higher than some other exon-skipping therapies in development, such as Sarepta Therapeutics' Exondys 51, which has shown lower levels of exon skipping.
• The company's INHBE program for obesity is showing preclinical results comparable to semaglutide, a leading GLP-1 agonist, but with the added benefit of no muscle loss and curtailed rebound weight gain, which could be a significant advantage over existing treatments.
• Wave's approach to Huntington's disease with WVE-003, which aims to selectively lower mutant HTT while sparing wild-type HTT, is a novel approach compared to non-selective HTT-lowering therapies being developed by companies like Roche and Ionis Pharmaceuticals.
• The company's RNA editing program, particularly WVE-006 for AATD, is a first-in-class approach, setting it apart from other companies focused on more traditional RNA interference or antisense technologies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the progress in clinical trials and collaborations.
• Employees may be motivated by the company's advancements in RNA medicines and the potential for future growth.
• Patients with AATD, DMD, and Huntington's disease may be hopeful about the potential for new treatments.
• The collaboration with GSK and Takeda may provide financial stability and resources for the company's programs.
• Suppliers and creditors may be reassured by the company's strong cash position.

Next Steps

• Wave expects to deliver proof-of-mechanism data from the RestorAATion-2 trial in AATD in 2024.
• The company plans to initiate a clinical trial for its INHBE candidate in obesity in the first quarter of 2025.
• Wave anticipates delivering potentially registrational 24-week dystrophin data from the FORWARD-53 trial in DMD in the third quarter of 2024.
• The company expects to report data from the 30 mg multi-dose cohort of the SELECT-HD trial with extended follow-up in the second quarter of 2024.
• Wave will continue to advance its pipeline of wholly owned RNA editing therapeutics across a range of targets.
• The company will continue to advance its collaboration programs with GSK.

Key Dates

Keywords

RNA medicines, RNA editing, siRNA, AATD, DMD, Huntingtons disease, obesity, clinical trials, GalNAc, GSK, exon skipping, antisense silencing